Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
Nick James, MD, PhD, The Institute of Cancer Research, London, United Kingdom, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a second-generation androgen receptor pathway inhibitor into their treatment regimen.
These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Parker C, Liu V, Mendes L, et al. Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 5001
